Cost effectiveness of exome and chromosomal microarray analysis in cases of severe central nervous system structural anomalies
Year: 2026
Type: article
Abstract: OBJECTIVE: The central nervous system (CNS) is affected in 9% of fetal malformations but accounts for as much as one-third of all pregnancy terminations due to fetal anomaly. When applying chromosomal microarray (CMA) to the diagnosis of fetal CNS anomalies, the estimated diagnostic yield remains low. Recent study demonstrated that, in fetuses with major CNS anomalies, exome sequencing (ES) had an additional diagnostic yield of 44% over the 10% provided by CMA. We aimed to determine the cost effectiveness of the added value of ES in major CNS structural anomalies. METHODS: We modeled costs, utility, and quality-adjusted life-years (QALYs) for CMA versus CMA + ES in prenatal testing. Two strategies were compared using the Markovian process decision analysis model: (1) CMA only, abnormal result culminating in termination of pregnancy (TOP); (2) ES after a negative CMA, where for positive result a TOP is conducted. The outcomes included health quality of life after TOP or having a disabled child, the costs of the CMA test, the ES test, and the health expenses of a disabled child. The time horizon of the model was 20 years. Sensitivity analysis including probabilistic sensitivity analysis of all parameters was conducted. RESULTS: In the base-case model, the total expected cost per pregnancy was $US 91 059 for the CMA-alone strategy (driven largely by the expected long-term cost of raising a child with an undiagnosed disability) and $US 3101 for the CMA + ES strategy. The QALYs with a time horizon of 20 years were 11.84 and 13.84 for CMA and CMA + ES strategies, respectively, so CMA + ES dominated CMA alone (higher QALY value and cost saving). Sensitivity analysis revealed that the results were robust, and CMA + ES dominated the CMA with cost savings for all sensitivity analysis. CONCLUSIONS: We suggest that ES has the potential to be cost effective and should be considered as a first-tier test in the prenatal diagnosis of major CNS anomalies. The substantial increase in diagnostic yield offered by ES not only provides valuable information for the current pregnancy but also holds significant relevance for future pregnancies. These findings are pivotal in facilitating timely and evidence-based decision-making.
DOI: 10.1002/ijgo.71480
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
OpenAlex ID: W7237346192
